[1]
|
张美琴. TNFSF15基因多态性与Graves眼病遗传易感性研究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2020.
|
[2]
|
Zhou, F., Liang, Z., Wang, X., Tan, G., Wei, W., Zheng, G., et al. (2021) The VDR Gene Confers a Genetic Predisposition to Graves’ Disease and Graves’ Ophthalmopathy in the Southwest Chinese Han Population. Gene, 793, Article ID: 145750. https://doi.org/10.1016/j.gene.2021.145750
|
[3]
|
Maciejewski, A., Kowalczyk, M.J., Gasińska, T., Szeliga, A., Prendecki, M., Dorszewska, J., et al. (2019) The Role of Vitamin D Receptor Gene Polymorphisms in Thyroid-Associated Orbitopathy. Ocular Immunology and Inflammation, 28, 354-361. https://doi.org/10.1080/09273948.2019.1629605
|
[4]
|
Paik, J.S., Kim, S., Kim, J.H., Lee, J., Yang, S. and Lee, S. (2020) Insulin-like Growth Factor-1 Enhances the Expression of Functional TSH Receptor in Orbital Fibroblasts from Thyroid-Associated Ophthalmopathy. Immunobiology, 225, Article ID: 151902. https://doi.org/10.1016/j.imbio.2019.151902
|
[5]
|
Smith, T.J. (2021) Insulin-like Growth Factor Pathway and the Thyroid. Frontiers in Endocrinology, 12, Article 653627. https://doi.org/10.3389/fendo.2021.653627
|
[6]
|
刘雪. IGF-IR在甲状腺相关眼病中的作用机制及相关治疗进展[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2019.
|
[7]
|
Krieger, C.C., Sui, X., Kahaly, G.J., Neumann, S. and Gershengorn, M.C. (2021) Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism, 107, e1653-e1660. https://doi.org/10.1210/clinem/dgab824
|
[8]
|
Fernando, R., Caldera, O. and Smith, T.J. (2021) Therapeutic IGF-I Receptor Inhibition Alters Fibrocyte Immune Phenotype in Thyroid-Associated Ophthalmopathy. Proceedings of the National Academy of Sciences of the United States of America, 118, e2114244118. https://doi.org/10.1073/pnas.2114244118
|
[9]
|
Li, Q., Yang, C., Liu, C., Zhang, Y., An, N., Ma, X., et al. (2024) The Circulating Il-35+ Regulatory B Cells Are Associated with Thyroid Associated Opthalmopathy. Immunity, Inflammation and Disease, 12, e1304. https://doi.org/10.1002/iid3.1304
|
[10]
|
Pan, Y., Wang, M., Chen, X., Chen, Y., Ai, S., Wang, M., et al. (2021) Elevated IL-38 Inhibits IL-23R Expression and IL-17A Production in Thyroid-Associated Ophthalmopathy. International Immunopharmacology, 91, Article ID: 107300. https://doi.org/10.1016/j.intimp.2020.107300
|
[11]
|
Shi, L., Ye, H., Huang, J., Li, Y., Wang, X., Xu, Z., et al. (2021) IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism, 106, e3125-e3142. https://doi.org/10.1210/clinem/dgab154
|
[12]
|
Du, J., Wang, X., Tan, G., Wei, W., Zhou, F., Liang, Z., et al. (2021) Predisposition to Graves’ Disease and Graves’ Ophthalmopathy by Genetic Variants of IL2RA. Journal of Molecular Medicine, 99, 1487-1495. https://doi.org/10.1007/s00109-021-02111-0
|
[13]
|
Stöhr, M., Oeverhaus, M., Lytton, S.D., Horstmann, M., Zwanziger, D., Möller, L., et al. (2021) Predicting the Relapse of Hyperthyroidism in Treated Graves’ Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. Hormone and Metabolic Research, 53, 235-244. https://doi.org/10.1055/a-1373-5523
|
[14]
|
Nicolì, F., Lanzolla, G., Mantuano, M., Ionni, I., Mazzi, B., Leo, M., et al. (2020) Correlation between Serum Anti-TSH Receptor Autoantibodies (TRABs) and the Clinical Feature of Graves’ Orbitopathy. Journal of Endocrinological Investigation, 44, 581-585. https://doi.org/10.1007/s40618-020-01353-y
|
[15]
|
王靖文, 柳林, 马晓婧, 刘梦妍, 高素敏. TSHR基因内含子1多态性与山东潍坊地区汉族人群Graves’眼病关系分析[J]. 潍坊医学院学报, 2021, 43(3): 192-195, 199.
|
[16]
|
马超, 刘薇, 李凯军, 何剑峰. 甲状腺相关眼病免疫相关发病机制的研究现状与进展[J]. 眼科新进展, 2019, 39(8): 790-794.
|
[17]
|
冯晓婷. 225例甲状腺相关眼病患者的临床资料分析和核磁共振脂肪定量对评估病情的临床应用初探[D]: [硕士学位论文]. 广州: 南方医科大学, 2019.
|
[18]
|
刘莹, 朱武飞, 赵雅. 甲状腺相关眼病的临床防治进展[J]. 中国医药科学, 2023, 13(21): 53-56.
|
[19]
|
Janssen, J.A.M.J.L. and Smith, T.J. (2021) Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Cells, 10, Article 383. https://doi.org/10.3390/cells10020383
|
[20]
|
王璇璐, 彭年春, 胡颖. 中重度活动性Graves眼病药物治疗新进展[J]. 疑难病杂志, 2024, 23(5): 635-640.
|